The decision to begin prophylactic therapy for the treatment of migraine depends on the frequency and the severity of the attacks, and to what extent they alter the quality of life of the patients. According to the Diagnostic and Therapeutic Guidelines for migraine and cluster headache of the Italian Society for the Study of Headaches [1], the presence of at least 2 attacks of migraine per month or lasting 4 or more days per month, which do not completely respond to symptomatic therapy, are indications to begin prophylactic therapy.
Introduction
The decision to begin prophylactic therapy for the treatment of migraine depends on the frequency and the severity of the attacks, and to what extent they alter the quality of life of the patients. According to the Diagnostic and Therapeutic Guidelines for migraine and cluster headache of the Italian Society for the Study of Headaches [1] , the presence of at least 2 attacks of migraine per month or lasting 4 or more days per month, which do not completely respond to symptomatic therapy, are indications to begin prophylactic therapy.
A state of hyperexcitability of the cerebral cortex is considered the neuropathophysiologic basis of migraine, as in epilepsy, and in fact the two pathologies are often comorbid [2] . In a population study, Ottman and Lipton [3] demonstrated that epilepsy and migraine are closely linked pathologic conditions, independent of seizure aetiology, age at first onset and type of crisis. These features, which are shared by these pathologies characterised by attacks, suggest a common pathogenesis involving membrane excitability upon which the antiepileptic drugs can act.
From this point of view, the studies of efficacy and tolerability confirm and delineate antiepileptics as very promising drugs in the panorama of the prevention of migraine and other head pain.
Antiepileptic and antimigraine drugs act on the nociceptive mechanisms mediated by GABA or glutamate neurotransmission, or both [4] . GABA is the major inhibitory neurotransmitter in the central nervous system and its presynaptic release occurs by a calcium-dependent mechanism [5] . Valproate and gabapentin interfere with GABA metabolism, inhibiting its degradation and transformation into succinate [6] , and topiramate potentiates GABA-mediated inhibition by facilitating receptor action [7] . GABA binding to its receptors causes cellular hyperpolarisation and inhibition of postsynaptic transmission. All these drugs modulate the activity of calcium, sodium and potassium ion channels by hyperpolarising and stabilising the membrane [4] .
Sodium valproate
Sodium valproate, more frequently marketed as its stable coordination product, divalproate (divalproex sodium), is the only antiepileptic drug in the United States approved by the Food and Drug Administration for migraine prophylaxis, as has been demonstrated with excellent results in randomised clinical studies [5, [8] [9] [10] [11] [12] [13] [14] . In a more recent study conducted by Freitag et al. [8] , a reduction in the weekly frequency of headache was significantly greater in the study group than in the placebo group (p=0.006). The antiepileptic and antimigraine properties of sodium valproate are due to its effects on GABA-mediated neurotransmission, blockade of sodium and calcium ion channels, and modulation of the release of excitatory amino acids [15] . The strong membrane stabilising effect makes valproate the prophylactic drug of first choice in the case of headache with mood disturbance or epilepsy. The main side effects are somnolence, nausea and other gastrointestinal disturbances, alopecia, tremor and weight gain [15] . It may have possible teratogenic effects on neural tube development and thus it should not be used in case of pregnancy [15] . Chronic use at elevated dosages may cause hepatic toxicity [15] , and so it should be used with caution in subjects who are taking antiaggregants or anticoagulants because the association with valproate can interfere with haemostasis and coagulation [15] . It was shown that 21% of patients in preventive therapy with valproate stopped treatment due to undesirable effects, and this has lead to a debate on the utility of identifying, even using serum dosages of the drug, a minimum effective dose that does not cause serious undesirable effects [16] . Recently, studies on valproate have evaluated the intravenous administration of the drug, which seems to offer better results for chronic headache and for acute phase therapy [17] .
Among the new generation of antiepileptic drugs, many studies have investigated topiramate, gabapentin, lamotrigine and levetiracetam.
Topiramate
Topiramate, introduced for the first time in 1995 in AngloSaxon countries for the therapy of partial seizures, produces a membrane-stabilising effect by blocking sodium, calcium and potassium ion channels, and by modulating GABA and glutamate-mediated activity. Many recent studies, even those conducted in children [18] , have shown efficacy in migraine prophylaxis, both for migraine without aura and presently also for that with aura [19] , and also in other forms of primary headache, yielding good results both in terms of frequency and efficacy at dosages of 100 mg/day [18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In a study just published, Brandes et al. [23] demonstrated that the average monthly headache crisis frequency was reduced significantly, even at the dosage of 100 mg/day of topiramate (p=0.008) as well as at that of 200 mg/day (p<0.001) compared to placebo. The most frequent side effects [30] of weight loss, paraesthesiae and dysgeusias were rarely caused by the discontinuation of therapy. These results make topiramate a very interesting molecule for migraine prophylaxis.
Gabapentin
Gabapentin interferes with the metabolism of GABA into its metabolite, succinate, and can modulate, as the other antiepileptic drugs, GABA-mediated neurotransmission [31] . It may also be involved in the inhibition of sodium and calcium ion channels [31] . Gabapentin is currently used in the treatment of chronic pain syndromes, such as SUNCT, trigeminal neuralgia or cluster headache [32] . The study of gabapentin in migraine, with recent randomised, open studies [33] and double-blind studies with placebo [34, 35] , are yielding positive results. In the study of Jimenez-Hernandez et al. [33] , a statistically significant difference was found between the treatment with gabapentin and the baseline condition of the patients, both for the reduction in the number of attacks and for the reduction in intensity and increase in the pain-free intervals. The most frequent side effects were somnolence and vertigo, symptoms well tolerated by the patients [31] .
Lamotrigine
Lamotrigine is an antagonist of glutamate-mediated activity due to its blockade of voltage-dependent sodium ion channels [31] . It is a well-tolerated drug and the most undesirable effect is skin rash [31] . Studies on the use of lamotrigine for headache have yielded contrasting results; in one study it furnished significant data only for migraine with aura [36] [37] [38] .
Levetiracetam
Levetiracetam, a new antiepileptic drug used as adjunctive therapy in the treatment of partial crises with or without generalisation, has a mechanism of action which is mostly unknown [31] . It acts selectively on autonomous neuronal activity, without any effect on normal neuronal characteristics. Specific receptor binding has not been shown, although recently the ability to selectively inhibit some voltage-dependent ion channels has been demonstrated [39] . The drug is well tolerated and the undesirable effects, though rare, are: somnolence, asthenia and postural instability [31] . For migraine therapy, few studies S69 are available in the literature regarding the use of levetiracetam for both the prophylaxis and attack of migraine. These studies have yielded encouraging results [40] [41] [42] [43] , even in children, with a recent retrospective study [44] .
Conclusions
In the last few years, the use of antiepileptic drugs in migraine prophylaxis has become ever more widespread.
The efficacy of many of these drugs has been confirmed by diverse placebo-controlled studies.
The mechanism that underlies the efficacy of antiepileptic drugs in migraine prophylaxis seems to be related to its ability to modulate GABA or glutamatemediated neurotransmission, or both, in the disequilibrium between neuronal inhibition and excitation, which has been hypothesised for migraine. The data presented here are very encouraging for the clinician, who thus possesses a valid alternative for consideration in the prophylactic therapy of migraine.
